Unbiased and Practical Psychopharmacology Updates For Prescribers

Recent articles and videos

Geriatric Psychopharmacology: How Pharmacokinetic and Pharmacodynamic Changes Affect Prescribing

Sandra A. Jacobson, M.D. Research Associate Professor University of Arizona College of Medicine-Phoenix   In terms of pharmacokinetic changes, aging slows hepatic metabolism. However, liver function tests are poorly correlated with drug metabolizing activity. Normal aging does not affect glucuronidation reactions, but it does affect oxidation reactions. Psychotropics metabolized by glucuronidation are preferred in the…

Treatment-Resistant Depression: Augmentation with Second-Generation Antipsychotics (Aripiprazole vs Quetiapine)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation compares advantages and disadvantages of using quetiapine vs. aripiprazole as augmentation for treatment-resistant depression. It also addresses the common question of when to augment (antidepressant + SGA) vs. when to switch (prescribing a different antidepressant). Combination and Augmentation: Clarifying Concepts…

Inflammation and Depression: Use of Anti-Inflammatory Agents and The Role of Inflammatory Markers (CRP)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation summarizes recent findings on the role of inflammation in depression. A study suggests patients with elevated levels of inflammatory markers (C-reactive protein) have a differential response to a specific antidepressant. The efficacy of celecoxib and infliximab in treatment-resistant depression is…

2018 APA Alcohol Use Disorder Guideline: Summary of Recommendations

By Flavio Guzman, MD Editor Psychopharmacology Institute The American Psychiatric Association (APA) released a new practice guideline on the treatment of alcohol use disorder. We reproduce below a summary of selected recommendations on pharmacotherapy. Pharmacotherapies for Alcohol Use Disorder Naltrexone or Acamprosate APA recommends (1B) that naltrexone or acamprosate be offered to patients with moderate…

2017 in Review: New Drugs, Formulations and Clinical Guidelines

Author: Flavio Guzman, MD Dr. Guzman has no conflicts of interest to disclose. In this article, we look back at the most clinically relevant news of 2017 in the field of psychopharmacology. In terms of new drugs, two medications were approved for the treatment of tardive dyskinesia: valbenazine (Ingrezza) and  deutetrabenazine (Austedo). This publication also summarizes…

Cannabis: Currently Approved Indications and Therapeutic Potential

Dr. Paul Morrison Clinical Senior Lecturer Institute of Psychiatry King’s College London NHS Consultant Psychiatrist The Maudsley Hospital, London       This presentation reviews indications for currently approved cannabis products (dronabinol and nabilone). It also discusses the therapeutic potential of CBD in psychiatry (psychosis) and other medical conditions (epilepsy, oncology). In this section, we’ll…

Trazodone for Disturbed Sleep Initiation in PTSD

David N. Osser, MD Associate Professor of Psychiatry Harvard Medical School Brockton Division of the VA Boston Healthcare System In this video, Dr. David Osser reviews the evidence base for the use of trazodone in PTSD patients with disturbed sleep initiation. He also comments on side effects, with a focus on priapism. This video is…

Understanding Cannabis in Psychiatry: Pharmacology and Synthetic Cannabinoids

Dr. Paul Morrison   Clinical Senior Lecturer Institute of Psychiatry King’s College London   NHS Consultant Psychiatrist The Maudsley Hospital, London     This presentation discusses cannabinoid pharmacology and synthetic cannabinoids. The endocannabinoid system consists of: CB1 and CB2 receptors, anandamide, 2‐arachidonoylglycerol (2-AG). Regarding synthetic cannabinoids, they are CB1 full agonists and their effect is…

Antipsychotics News: Cariprazine, Risperidone and New Drug Applications

Author: Flavio Guzman, MD Editor Psychopharmacology Institute Dr. Guzman has no conflicts of interest to disclose. Cariprazine for Negative Symptoms of Schizophrenia: The FDA Refuses to Review Supplemental New Drug Application (sNDA) The FDA has refused Allergan’s request to review a Supplemental New Drug Application (sNDA) to expand the approved uses to include negative symptoms of schizophrenia…

Buprenorphine for Opioid Use Disorder: Mechanism of Action

By Joji Suzuki, MD Director, Division of Addiction Psychiatry Department of Psychiatry Brigham and Women’s Hospital Assistant Professor of Psychiatry Harvard Medical School This presentation reviews the mechanism of action of buprenorphine in the treatment of opioid use disorders. Dr. Suzuki explains how partial agonism and high affinity for mu opioid receptors increases the risk of…

PDF: LAI Antipsychotics

Screenshot 2017 01 07 12.39.54

Free PDF Download

  • New formulations (Aristada, Invega Trinza)
  • Practical dosing tables
Powered by ConvertKit